Tessera Defense and Homeland Security Inc. (HLSQ) is a NYSE American-listed physical security technology company that operates a unified platform connecting cameras, sensors, detection technologies, artificial intelligence and other security infrastructure. News related to Tessera often focuses on how the company develops and deploys integrated security solutions for homeland security, critical infrastructure, energy, digital infrastructure and enterprise environments.
Coverage of Tessera can include announcements about enhancements to its unified security platform, updates on deployments that connect detection, intelligence and response across complex sites, and developments involving its subsidiaries. Zorronet, which provides AI-powered security intelligence and autonomous command-and-control capabilities, and DFSL, which develops LADAR-based counter-UAS and perimeter security systems, may feature in reports about advanced sensing, real-time intelligence and autonomous response applications.
Another important theme in Tessera-related news is its corporate evolution. On September 11, 2026, the company changed its legal name from BiomX Inc. to Tessera Defense and Homeland Security Inc. and began trading under the HLSQ ticker, replacing PHGE. Articles and releases may reference this transition and explain that older items under the BiomX name or PHGE symbol document the issuer’s former biotechnology business rather than its current security focus.
Investors, analysts and security professionals following Tessera’s news can expect information about platform capabilities, customer segments such as critical infrastructure and homeland security organizations, and the company’s role in addressing evolving physical threats, including those involving unmanned and autonomous systems. Historical news under the BiomX identity remains part of the record but should be interpreted in light of the company’s subsequent shift to physical security technology.
BiomX Inc. (PHGE) will host a virtual key opinion leader webinar on May 26, 2021, at 8:00 AM EDT, focusing on BX003, a phage therapy targeting Klebsiella pneumoniae for inflammatory bowel disease (IBD). Dr. Ryan Balfour Sartor, a leading expert, will discuss the efficacy of microbiome-based treatments. Following a successful Phase 1a study, BiomX aims to enter Phase 1b/2a trials evaluating BX003's safety and efficacy, with results expected by Q2 2022. Registration is available on BiomX's investor website.
BiomX Inc. (PHGE) announced a conference call on May 24, 2021, at 8:00 a.m. EDT to report its first quarter 2021 financial results and provide updates on business progress. The call will be accessible via phone and webcast on the Company’s website. BiomX is focused on developing natural and engineered phage therapies to combat specific pathogenic bacteria impacting skin health and chronic diseases including inflammatory bowel disease and colorectal cancer.
BiomX (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at two virtual investor events in April 2021. The first is the Jefferies Microbiome-Based Therapeutics Summit on April 22, available on-demand from 8:00 AM EDT. The second is the Ladenburg Thalmann R&D Showcase on April 29 at 1:00 PM EDT, where Solomon will discuss the acne landscape and the lead product candidate, BX001, alongside Dr. Leon Kircik. Webcasts can be accessed on the company’s website.
BiomX (NYSE American: PHGE) reported its fourth quarter and full year financial results for 2020, highlighting significant advancements in its pipeline, including new phage cocktail candidates BX004 and BX005 targeting cystic fibrosis and atopic dermatitis. The company anticipates key efficacy data from two Phase 2 studies in 2021. Financially, BiomX ended 2020 with a cash balance of $57.1 million, down from $82.4 million in 2019, primarily due to increased operational costs. The net loss for the year increased to $30.1 million from $20.6 million in the prior year.
BiomX (NYSE American: PHGE) plans to host a conference call on March 31, 2021, at 8:00 a.m. EDT to discuss its fourth quarter and full year 2020 financial results. The call will be accessible via phone and an archived webcast will be available on their website. BiomX specializes in developing phage therapies targeting pathogenic bacteria linked to skin conditions and chronic diseases, including inflammatory bowel disease and colorectal cancer. Their innovations focus on creating customized phage cocktails to effectively combat these bacterial targets.
BiomX (NYSE American: PHGE) has initiated a Phase 2 clinical study for BX001, a topical gel aimed at treating mild-to-moderate acne. The trial, involving 140 participants, will evaluate the safety and efficacy of BX001 over 12 weeks. This significant step follows promising Phase 1 results, which showed a statistically significant reduction in C. acnes levels compared to placebo. Results from the interim 8-week assessment are anticipated in Q3 2021, with comprehensive results expected in Q4 2021.
BiomX (NYSE American: PHGE), a clinical-stage biotechnology company, announced that CEO Jonathan Solomon will present at two virtual investor conferences in March 2021. The first event is Chardan’s 3rd Annual Microbiome Medicines Summit on March 8, 2021, at 10:45 AM EST. The second is H.C. Wainwright's Global Life Sciences Conference on March 9, 2021, with on-demand access starting at 7:00 AM EST. The presentations will be available for streaming on the company’s website, offering insights into BiomX's development of phage therapies targeting specific pathogenic bacteria.
BiomX Inc. (PHGE) announced positive results from its first-in-human Phase 1a study of BX002, an orally administered phage therapy targeting Klebsiella pneumoniae. The study demonstrated BX002 is safe and well-tolerated, with no serious adverse events. It successfully delivered high concentrations of viable phages, approximately 1010 PFU, significantly exceeding bacterial burden in patients. Following these results, BiomX plans to advance to a Phase 1b/2a study for BX003 aimed at reducing K. pneumoniae in targeted individuals, with results expected by mid-2022.
BiomX (NYSE American: PHGE), a clinical-stage biotechnology company, has announced that CEO Jonathan Solomon will participate in two upcoming investor conferences. The H.C. Wainwright BioConnect Conference is scheduled for January 11-14, 2021, with a playback available at 6 a.m. EST on January 11. Additionally, the Oppenheimer Virtual Banking Meeting will occur during the same dates with one-on-one meetings only. BiomX focuses on developing natural and engineered phage therapies targeting bacteria affecting skin health and chronic diseases.